cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study.
A total of 26 patients with biopsy proved epidermoid carcinoma of the penis (Jackson stage III or IV) with measurable disease, no prior chemotherapy and adequate renal function received 50 mg. per M.2 cis-diamminedichloroplatinum intravenously on days 1 and 8 of 28-day cycles. There were 4 partial responses (15.4 per cent), with a response duration of 1 to 3 months. The median survival was 4.7 months. This agent cannot be recommended as treatment for advanced epidermoid carcinoma of the penis using this particular dose and schedule.
Gagliano
R G
RG
Humana Hospital Sunrise, Las Vegas, Nevada.
Blumenstein
B A
BA
Crawford
E D
ED
Stephens
R L
RL
Coltman
C A
CA
Costanzi
J J
JJ
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D010412:Penile Neoplasms / Q000188:drug therapy* / Q000401:mortality
D002945:Cisplatin